Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy is a phase 3 interventional study registered as NCT00716976 by Children's Oncology Group, with 131 participants recorded, started 2008-06-23 and reaching its primary completion in 2015-04-09. Interventions recorded: sodium thiosulfate, examination. Conditions recorded: Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ototoxicity, Ovarian Cancer, Sarcoma.

Linked to the drug Sodium thiosulfate because the registry names it among its interventions and Extragonadal germ cell tumour, Hepatocellular carcinoma, Neuroblastoma and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.